HIMS Stock — Hims & Hers Health Inc.

Hims & Hers Health Inc. (HIMS)

Updated October 16, 2026.

HIMS is a Stock. Total return is 186.4% over the past 7.1 years, 4.9 points ahead of SPY at 181.5%.

Hims & Hers Health operates a consumer-first telehealth platform that connects patients with licensed healthcare professionals across the United States and nine other countries, offering prescription medications, over-the-counter products, supplements, cosmetics, and laboratory testing services through its website and mobile app, with a focus on areas including sexual health, hair care, skincare, weight loss, and mental health. The company does not currently distribute dividends to shareholders. This stock appeals to growth-oriented investors seeking exposure to digital healthcare and telehealth services rather than those focused on dividend income.

HIMS performance versus SPY

Price and return data through 2026-10-16.

Total return is 186.4% over the past 7.1 years, 4.9 points ahead of SPY at 181.5%. Over the past year its total return — price change plus distributions reinvested — is -52.5%. Its deepest 1-year drawdown was 75.5%.

HIMS key facts

Asset type

Stock

Asset class

Equity

Inception date

09/13/2019

Distribution frequency

None

Last close

$28.07 (as of 2026-10-16)

Market cap

$6,313,947,625

Average volume

10996300.0

Beta

2.432

Payout ratio

0.0%

Forward P/E

73.5294

EPS

$-0.64

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HIMS risks and drawbacks

The deepest 1-year drawdown on record here is 75.5%.

Who may consider HIMS — and who may not

It is a weaker fit for investors who need monthly cash flow (HIMS does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on HIMS

• All tickers starting with H

Tagged: Healthcare, Pharmaceutical.

Compare HIMS

HIMS vs similar funds:

• HIMS vs HMYY

Frequently asked questions